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INTRODUCTION
Growth hormone (GH) is a potent anabolic agent, with multiple effects on lipid and carbohydrate metabolism. Recently, the effects of recombinant human GH (rhGH) in adult man with GH deficiency have been examined in two controlled treatment trials. Major increases in lean body mass [l] and skeletal muscle mass [2, 31 have been demonstrated, reflecting the anabolic action of GH. Similar anabolic responses have been seen when GH has been given to adult patients with burns [4], after gastrointestinal surgery [5] , with malnutrition [6] and with chronic obstructive airways disease [7] , and when given to elderly male subjects [8] .
GH treatment in adults with GH deficiency has resulted in major improvements in exercise performance [3, 9] . Since cardiac output is generally considered to be a major determinant of exercise performance and GH has antinatriuretic effects, we report resting cardiac function, determined by M-mode echocardiography, and plasma levels of hormones regulating blood volume in a group of adults with GH deficiency before and after rhGH treatment, and we relate these to changes in exercise performance.
METHODS Patients
The study reported here involves the same patients as previously reported [ l , 3, 91 . Briefly, patients were selected if (a) GH deficiency (defined as a peak plasma G H concentration of < 3 m-units/l during an adequate insulin hypoglycaemia test) had been present for 12 months, (b) their age was between 18 and 52 years, and (c) if required, stable and optimal conventional pituitary hormone replacement was given for 12 months before entry into the trial. Doses of these hormone replacements remained unchanged during the trial, except in three patients in the rhGH group, where thyroxine doses were reduced at 1 month to maintain free tri-iodothyronine levels within the reference range [ 11. Patients with Cushing's disease were all cured more than 12 months before entry to the trial. Patients with other illnesses or ingesting drugs or alcohol sufficient to affect myocardial function or sodium balance were excluded.
Trial design
The protocol was approved by the hospitals' ethics committees and all patients gave written, informed consent. Patients were randomly assigned to receive either rhGH (Genotropin; 4 i.u./ml, 2.7 i.u./mg; KabiVitrum, Stockholm, Sweden) or identically presented placebo, for 6 months, given as a daily subcutaneous dose of 0.07 unit/kg body weight at 20.00 hours. Women were studied in the first half of their menstrual cycle where appropriate.
Echocardiography
Patients requiring pituitary hormone treatment took their usual medications on the morning of the study. Parasternal long-axis images were recorded just below the mitral valve using a Hewlett-Packard machine (model 77020 AC) with the patient in the left lateral position. A single observer, blinded to the treatment code and patient details, performed all measurements. Left ventricular end-diastolic wall thicknesses [interventricular septa1 (IVS) and posterior wall (LVPW)], and internal dimensions [end-diastolic (LVED) and end-systolic (LVES)] were recorded to the nearest 0.1 cm.
Blood was collected via a plastic venous catheter after an overnight fast, at least 30 min after the subject had assumed the recumbent position. Plasma was separated and was stored at -20°C until assayed. Brachial blood pressure was then recorded, as the average of three sphygmomanometric recordings in the non-dominant arm at baseline and after 1, 3 and 6 months of treatment. Plasma renin activity (PRA) was measured by established methods [lo] . Plasma aldosterone concentration was measured by r.i.a. [ 111 after solvent extraction using the DPL Aldosterone Kit [DPL (U.K.) Ltd, Abingdon, Oxon, U.K.]. Intra-and inter-assay coefficients of variation for PRA were less than 5.2% and 7.0%, and for plasma aldosterone concentration were less than 6.9% and 7.8%, respectively. Maximal oxygen uptake ( V O~, , ,~~, ) was measured on a cycle ergometer on the day preceding echocardiography, as previously reported [9] .
Calculations
Mean arterial blood pressure was calculated as: diastolic pressure + 1/3 X (systolic -diastolic pressure).
Diastolic and systolic volumes were determined as: 
Statistics
Results are expressed as means k SEM. Treatment responses were assessed by analysis of co-variance using baseline data as the co-variate, and where repeat measures were made a mean of treatment data was used for comparison. Significance was recognized at the 5% level. Reported percentage changes in variables are those in excess of changes in the placebo group. Relationships between changes in single variables in the two groups were explored with multiple linear regressions, using treatment group as a stratifying variable.
RESULTS
Randomization resulted in two evenly matched populations with respect to age, sex, body size and drug history (see Table 1 ). Two patients in each group had undergone a (Table 2) . LVED increased by 2% in the rhGH group (P= 0.039). Fractional shortening was significantly lower in the rhGH group at baseline ( P = 0.004), but the increment after treatment was not different between the two groups (P = 0.77). Stroke volume increased by 6.1% in the rhGH group ( P = 0.001). Left ventricular wall mass increased by 4.8% in the rhGH group (P=O.O45; see Fig. 1 ). Because there was no change in body weight after rhGH treatment [ 13, left ventricular wall mass expressed per body surface area showed equally significant changes (rhGH, 110 f 10 to 120f 10 g/m2; placebo, 100 f 10 to 100 f 10 g/m2; P = 0.046).
Mean arterial blood pressure increased slightly, but not significantly, at 1 month and was not different between the groups (rhGH, 87 f 3, 96 f 4, 91 f 2 and 88 f 3 mmHg; placebo, 93 f 3,95 f 4,94 f 5 and 90 k 4 mmHg; see Fig. 2). One patient became hypertensive at 1 month (blood pressure 141/105 mmHg); subsequent halving of the rhGH dose resulted in a prompt normalization of blood pressure for the remainder of the trial. In two other Left ventricular wall mass (gm) patients, the rhGH dose was halved due to carpal tunnel compression symptoms or peripheral oedema. One patient in the rhGH group withdrew after 3 days treatment due to agitation.
The mean PRA in adults with GH deficiency before treatment was 2.43 f 0.28 (range 1.38-6.1 1) pmol of angiotensin I (ANG I) h-' ml-I in patients with intact zona glomerulosae (95% confidence intervals for normal samples collected after overnight recumbency, 1.14-2.65 pmol of ANG I h-I ml-I). In the patients with previous adrenalectomies, PRA was 2.84, 4.12, 5.55 and 17.2 pmol of ANG I h-I ml-*, and plasma aldosterone concentrations were undetectable. The plasma aldosterone concentration in the patients with intact adrenals was 199 f 28 pmol/l (recumbent reference range, 100-400 pmol/l). In patients with intact adrenals after treatment, PRA rose in the rhGH group and remained elevated throughout the trial (rhGH, 2.64f0.32, 3.08f0.42, 3.18k0.42 and 3.02f0.38 pmol of ANG I h-I ml-' at entry, 1, 3 and 6 months, respectively; placebo, 2.22 f 0.44, 1.86f0.22, 1.78f0.26 and 2.01f0.27pmolofANGI concentration did not change appreciably in either group (rhGH, 185f34,144+24,163+34and 1 5 2 f 3 5 pmol/ 1; placebo, 211f45, 200f41, 1 6 8 f 3 2 and 1 9 8 f 2 5 pmol/l). Treatment data were analysed after excluding patients with prior adrenalectomies, although the conclusions were not altered by their inclusion. As previously reported [ 11, the plasma potassium concentration fell marginally after rhGH treatment (rhGH, 3.8 f 0.1, 3.6f0.1, 3.7f0.1 and 3.6f0.1 mmol/l; placebo, 3.7k0.1, 3.7f0.1, 3.9f0.1 and 3.8f0.1 mmol/l at entry, 1, 3 and 6 months, respectively; P=O.O5). The plasma sodium concentration was normal and was unaffected by treatment with rhGH.
As previously reported [9], vo2,max. Changes in left ventricular wall mass were associated with changes in stroke volume ( P = 0.01 3), but not with the changes in lean body mass, thigh muscle mass, plasma insulin-like growth factor-1 (IGF-1) concentration, volmax,, nor with the age or sex of the patients, nor with a history of cured Cushing's disease. Increases in left ventricular diastolic volume and wall mass were not associated with changes in mean arterial blood pressure from baseline to either 1 or 6 months.
DISCUSSION
GH treatment in adults with GH deficiency has been shown to increase and normalize lean body mass [l] , to increase skeletal muscle mass [2, 31, to substantially reduce fat mass [ l , 21 and to increase maximal [2,9] and sub-maximal [9] exercise performance.
We have shown an increase in left ventricular myocardial wall mass of approximately 5% after rhGH treatment in adults with GH deficiency, comparable with increases in thigh muscle (5-8'/0) and lean body (approximately looh) mass in the same patients [l, 31. Atrophy of visceral organs after hypophysectomy has been shown to include the heart [ 141. Treatment of hypophysectomized rats with either human GH or human IGF-1 significantly increased heart weight, suggesting that this anabolic action of GH is mediated by IGF-1 [15] . No correlation between the plasma IGF-1 concentration and the myocardial mass could be shown, due to either insufficient numbers of patients or to alterations in serum IGF-1-binding proteins or in IGF-1 receptor status. While changes in lean body mass might be expected to be paralleled by changes in myocardial mass, the absence of such an association probably reflects the small number of patients studied.
Cardiomegaly in human acromegaly is usually, but not always, associated with hypertension [ 16, 171. The cardiomegaly resulting from implantable GH-secreting tumours appears to be due to both direct cardiac effects (anabolism) and volume overload [ 181. Since no increase in training activities was recorded [9] and no statistically significant effect from changes in systemic arterial blood pressure were detected, the increase in left ventricular myocardial wall mass most likely reflected the anabolic action of rhGH.
We attempted to minimize the variability involved in the measurement of left ventricular wall mass and volumes by echocardiography [12, 13, 371 by the use of a single echocardiographer, blinded as to the treatment code, and by using well-validated procedures. Due to the age of the patients and the successful completion of maximal exercise tests, ventricular asynergy was considered unlikely, allowing the assumptions in the calculations of ventricular volumes [12] and wall mass [13] to be met. The statistical design, testing for differences in mean responses between rhGH and placebo groups, accounts for this variability. The lack of change in myocardial wall mass in young GH-deficient adults treated with rhGH for 4 months [2] may thus reflect the lower dose and/or the shorter duration of treatment.
This study demonstrated small increases in resting LVED. Admittedly, these changes were at the limit of detectable changes with echocardiography, but they are consistent with the clinical signs of sodium retention noted in this trial [l] , particularly during the first 3 months. Sodium retention and/or reduced urinary sodium excretion have been noted after GH treatment in GHdeficient [2, 19, 201 and normal [21] human subjects. Extracellular fluid volume has been shown to increase with GH treatment in GH-deficient children [22] . Patients with acromegaly have increased plasma and erythrocyte volumes [23] , total body water and total body sodium contents [24] , and extracellular/intracellular water ratio [25] . Thus the increase in LVED has been interpreted as an increase in pre-load secondary to increased circulating blood volume.
That improved maximal exercise performance was associated with increased resting LVED suggests that the observed echocardiographic changes were beneficial. The increases in maximal oxygen pulse [9], an index of maximal stroke volume, supports the contention that some of the improvement in exercise performance was related to increased cardiac output.
GH-induced sodium retention involves the renal tubules [26] , a process stimulated directly by IGF-1 [27, 281. The antinatriuresis can occur independently of the adrenal glands [26, 291. The increase in PRA demonstrated in this study suggests an additional factor, activation of the renin-aldosterone system, after long-term GH replacement. The lack of suppression of plasma aldosterone concentrations in the face of an apparent increase in blood volume supports this contention. Similarly, the small reduction in plasma potassium concentration in the rhGH-treated group may have contributed to the reduced aldosterone response to the PRA stimulus.
An [34] aldosterone systems, usually with suppressed PRA, have been reported. The variety of alterations in the renin-aldosterone system described in acromegaly may reflect the chronicity of volume expansion and the dual mechanisms of sodium retention by GH and IGF-1.
The increase in stroke volume after rhGH treatment may reflect increased pre-load (the Starling effect) or possibly enhanced myocardial contractility. In neonatal rat cardiocytes, increased contractility has been noted after the addition of IGF-1 at physiological concentrations [35] . Increases in myocardial contractility (measured as increased fractional shortening) have been reported in some patients with acromegaly [17, 361, in normal subjects treated with human GH for 2 weeks [37] , and in one patient with GH deficiency and cardiomyopathy [38] . No such change was noted in the present study. Whether the reported change in fractional shortening was due to increased contractility or to reduced after-load is uncertain.
In summary, echocardiographic studies before and 6 months after rhGH treatment (0.07 unit/kg) in adults with GH deficiency showed an increased left ventricular wall mass, reflecting the anabolic action of GH. Secondly, small increases in LVED and stroke volume were noted, probably due to increased circulating blood volume. Finally, the antinatriuretic effect of rhGH treatment involves, in part, stimulation of the renin-aldosterone system.
